Cargando…
The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine
BACKGROUND: Early stage gastric cancer diagnosis has ensued different approaches in resection strategies. In order to increase the proportion of cases which have undergone radical resection or have reduced the recurrence rate, different pre-operative treatments have introduced. Here, we have verifie...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Research Center, Shahid Beheshti University of Medical Sciences
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142926/ https://www.ncbi.nlm.nih.gov/pubmed/25250123 |
_version_ | 1782331836147433472 |
---|---|
author | Yahyazadeh-Jabbari, Seyyed-Hossein Malekpour, Nasser Salmanian, Bahram Foodazi, Hossein Salehi, Masoud Noorizadeh, Farsad |
author_facet | Yahyazadeh-Jabbari, Seyyed-Hossein Malekpour, Nasser Salmanian, Bahram Foodazi, Hossein Salehi, Masoud Noorizadeh, Farsad |
author_sort | Yahyazadeh-Jabbari, Seyyed-Hossein |
collection | PubMed |
description | BACKGROUND: Early stage gastric cancer diagnosis has ensued different approaches in resection strategies. In order to increase the proportion of cases which have undergone radical resection or have reduced the recurrence rate, different pre-operative treatments have introduced. Here, we have verified an active preoperative chemotherapeutic regimen in locally advanced gastric cancer patients. METHODS: Forty nine patients who have found eligible to enter this phase 2 trial have treated with oxaliplatin 100 mg/m2 IV, docetaxel 50 mg/m2 IV, plus capecitabine 625 mg/m2 PO (TOX). Clinical staging has been following the first 2 cycles of induction chemotherapy. Patients that have further undergone radical surgery, have evaluated for pathological response rate. RESULTS: Anemia (10.2%), nausea (10.2%) and vomiting (6.1%) were the most frequent grade 3 or 4 adverse effects. Regarding the pathologic staging, 6 patients (12.2%) had complete response (95% CI 3% to 21.4%), 18 of them (36.7%) had partial response (95% CI 23.2% to 50.2%), then 3 patients (6.1%) had stable disease (95% CI 0%-12.8%). Among the patients who had surgery, 22% had pathologic complete response. CONCLUSION: Preoperative chemotherapeutic regimen of TOX seems to be an active and safe neoadjuvant therapy in non metastatic gastric cancer. It should further be considered with concurrent radiotherapy. |
format | Online Article Text |
id | pubmed-4142926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Cancer Research Center, Shahid Beheshti University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-41429262014-09-23 The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine Yahyazadeh-Jabbari, Seyyed-Hossein Malekpour, Nasser Salmanian, Bahram Foodazi, Hossein Salehi, Masoud Noorizadeh, Farsad Iran J Cancer Prev Clinical Trial BACKGROUND: Early stage gastric cancer diagnosis has ensued different approaches in resection strategies. In order to increase the proportion of cases which have undergone radical resection or have reduced the recurrence rate, different pre-operative treatments have introduced. Here, we have verified an active preoperative chemotherapeutic regimen in locally advanced gastric cancer patients. METHODS: Forty nine patients who have found eligible to enter this phase 2 trial have treated with oxaliplatin 100 mg/m2 IV, docetaxel 50 mg/m2 IV, plus capecitabine 625 mg/m2 PO (TOX). Clinical staging has been following the first 2 cycles of induction chemotherapy. Patients that have further undergone radical surgery, have evaluated for pathological response rate. RESULTS: Anemia (10.2%), nausea (10.2%) and vomiting (6.1%) were the most frequent grade 3 or 4 adverse effects. Regarding the pathologic staging, 6 patients (12.2%) had complete response (95% CI 3% to 21.4%), 18 of them (36.7%) had partial response (95% CI 23.2% to 50.2%), then 3 patients (6.1%) had stable disease (95% CI 0%-12.8%). Among the patients who had surgery, 22% had pathologic complete response. CONCLUSION: Preoperative chemotherapeutic regimen of TOX seems to be an active and safe neoadjuvant therapy in non metastatic gastric cancer. It should further be considered with concurrent radiotherapy. Cancer Research Center, Shahid Beheshti University of Medical Sciences 2013 /pmc/articles/PMC4142926/ /pubmed/25250123 Text en © 2014 Cancer Research Center, Shahid Beheshti University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
spellingShingle | Clinical Trial Yahyazadeh-Jabbari, Seyyed-Hossein Malekpour, Nasser Salmanian, Bahram Foodazi, Hossein Salehi, Masoud Noorizadeh, Farsad The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine |
title | The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine |
title_full | The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine |
title_fullStr | The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine |
title_full_unstemmed | The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine |
title_short | The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine |
title_sort | phase 2 study of "(tox) preoperative chemotherapy" response rate and side effects in [locally advanced operable gastric adenocarcinoma] patients with docetaxel, oxaliplatin and capcitabine |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142926/ https://www.ncbi.nlm.nih.gov/pubmed/25250123 |
work_keys_str_mv | AT yahyazadehjabbariseyyedhossein thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT malekpournasser thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT salmanianbahram thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT foodazihossein thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT salehimasoud thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT noorizadehfarsad thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT yahyazadehjabbariseyyedhossein phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT malekpournasser phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT salmanianbahram phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT foodazihossein phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT salehimasoud phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine AT noorizadehfarsad phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine |